[1] Ling C, Qian S, Wang Q, et al. Pneumocystis pneumonia in non-HIV children: a 10-year retrospective study[J]. Clin Respir J,2018,12(1):16-22. DOI:10.1111/crj.12467.
[2] Salzer H, Schäfer G, Hoenigl M, et al. Clinical, diagnostic,and treatment disparities between HIV-Infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia[J]. Respiration, 2018,96(1):52-65. DOI:10.1159/000487713.
[3] Nettleton E, Sattui SE, Wallace Z, et al. Incidence of Pneumocystis Jiroveci pneumonia in patients with ANCA-associated vasculitis initiating therapy with rituximab or cyclophosphamide[J]. Arthritis Care Res, 2024, 76(2): 288-294. DOI:10. 1002/acr. 25222.
[4] Zhou LM, You XH, Zhang JN, et al. Pneumocystis pneumonia in patients with primary nephrotic syndrome[J]. Clin Nephrol, 2022, 97(4): 226-231. DOI:10. 5414/CN110679.
[5] 吴晓明,杨海明,郝静,等.儿童紫癜性肾炎合并耶氏肺孢子菌肺炎4例并文献复习[J]. 国际儿科学杂志,2022,49(10):718-722. DOI:10.3760/cma.j.issn.1673-4408.2022.10.016.
[6] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2018版)[J].国际流行病学传染病学杂志,2018,45(6):361-378. DOI:10.3760/cma.j.issn. 1673-4149.2018.06.001
[7] García-Moreno J, Melendo-Pérez S, Martín-Gómez MT, et al. Pneumocystis jirovecii pneumonia in children, a retrospective study in a single center over three decades[J]. Enferm Infecc Microbiol Clin (Engl Ed),2020,38(3):111-118. DOI:10.1016/j.eimc.2019.05.005.
[8] Li L, Hsu SH, Gu X, et al. Aetiology and prognostic risk factors of mortality in patients with pneumonia receiving glucocorticoids alone or glucocorticoids and other immunosuppressants: a retrospective cohort study[J].BMJ Open,2020,10(10):e037419. DOI:10.1136/bmjopen-2020-037419.
[9] Zhao Z, Huang Y, Ming B, et al. Characterization and associated risk factors of pneumocystis jirovecii pneumonia in patients with AIRD: a retrospective study[J].Rheumatology (Oxford),2022,61(9):3766-3776. DOI:10.1093/rheumatology/keab941.
[10] Ibrahim A, Chattaraj A, Iqbal Q, et al. Pneumocystis jiroveci pneumonia: a review of management in human immunodeficiency virus (HIV) and non-HIV immunocompromised patients[J]. Avicenna J Med, 2023, 13(1): 23-34. DOI:10. 1055/s0043-1764375.
[11] Hammarström H, Krifors A, Athlin S, et al. Treatment with reduced-dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with hematologic malignancies[J]. Clin Infect Dis, 2023, 76(3): e1252-e1260. DOI:10.1093/cid/ciac386.
[12] Li X, Li Z, Ye J, et al. Diagnostic performance of metagenomic next-generation sequencing for Pneumocystis jirovecii pneumonia[J]. BMC Infect Dis, 2023,23(1):455. DOI:10.1186/s12879- 023-08440-4.
[13] 龚金如,杨家盛,屈满英,等.非人类免疫缺陷病毒感染免疫抑制宿主耶氏肺孢子菌肺炎26例临床特征分析[J].中华全科医师杂志,2023,22(12):1295-1299. DOI:10.3760/cma.j.cn114798-20231014-00241.
[14] 曾秀洁.非HIV免疫抑制患者肺孢子菌肺炎的临床特征及预后分析[D].石家庄:河北医科大学,2022. DOI:10.27111/d.cnki.ghyku.2022.000757.
[15] 马雪晨,郑凌,马长秀. 非HIV感染者与HIV感染者肺孢子菌肺炎的临床特征比较及预后分析[J]. 临床肺科杂志,2024,29(12):1820-1827. DOI:10.3969/j.issn.1009-6663.2024.12.008.
[16] Iwatani Y, Amemiya N, Nokiba H, et al. Risk factors for cytomegalovirus reactivation in patients with kidney disease under immunosuppressive therapy[J]. Clin Exp Nephrol,2022;26(1):22-28. DOI:10.1007/s10157-021-02117-5.
[17] Imlay H, Limaye AP. Current understanding of cytomegalovirus reactivation in critical illness[J]. J Infect Dis,2020,221(Suppl 1):S94-S102. DOI:10.1093/infdis/jiz638.
[18] 李喆,王杨,罗松,等.巨细胞病毒血症对慢性肾脏病继发耶氏肺孢子菌肺炎预后的影响[J].肾脏病与透析肾移植杂志,2021,30(6):507-513. DOI:10.3969/j.issn.1006-298X.2021.06.002.
[19] 石慧鑫,蒋梦媛,邵煜涵,等.耶氏肺孢子菌肺炎研究进展[J].中国真菌学杂志,2024,19(2):206-210. DOI:10.3969/j.issn.1673-3827.2024.02.022.
[20] 沈存,许戎.免疫抑制治疗的肾脏疾病患者并发肺孢子菌肺炎的临床特点及死亡风险因素分析[J].中华预防医学杂志,2024,58(5):673-678.DOI:10.3760/cma.j.cn112150-20230823-00116.
[21] 段甲利,杨跃杰,刘秋红,等.人类免疫缺陷病毒感染与非人类免疫缺陷病毒感染免疫抑制肺孢子菌肺炎合并急性呼吸衰竭患者的临床特点比较[J].中华传染病杂志,2022,40(3):151-158. DOI:10.3760/cma.j.cn311365-20210614-00210.
[22] Kaminski H, Belliere J, Burguet L, et al. Identification of predictive markers and outcomes of late-onset Pneumocystis jirovecii pneumonia in kidney transplant recipients[J].Clin Infect Dis,2021,73(7):e1456-e1463. DOI:10.1093/cid/ciaa1611.
[23] Baulier G, Issa N, Gabriel F, et al. Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases[J]. Clin Exp Rheumatol,2018,36(3):490-493.
[24] 李飞,郭丽娟,吴京波,等. 非HIV患者新型冠状病毒感染恢复期继发耶氏肺孢子菌肺炎1例[J]. 国际医药卫生导报,2023,29(20):2937-2940. DOI:10.3760/cma.j.issn.1007-1245.2023.20.024.
[25] Assal M, Lambert J, Chow-Chine L, et al. Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with Pneumocystis jirovecii pneumonia: a propensity score analysis[J].PLoS One,2021,16(4):e0250611. DOI:10.1371/journal.pone.0250611.
[26] Ding L, Huang H, Wang H, et al. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies[J]. Ann Intensive Care, 2020,10(1):34. DOI:10.1186/s13613-020-00649-9.
[27] 陈朝英,涂娟.儿童肾病综合征合并重症感染的诊断和治疗[J].中国小儿急救医学,2021,28(7):557-561. DOI:10.3760/cma.j.issn.1673-4912.2021.07.003.
|